Dr. Vrljic has served as our Vice President, Antibody Technologies since October 2021. Prior to joining us, she was the Co-Founder and Chief Executive Officer of ScalmiBio, an oncology company founded in 2017 that developed the novel conversion of therapeutic antibodies into prodrugs activated specifically within tumors. From 2015 to 2017, she was an independent consultant providing scientific guidance to biotechnology companies. From 2013 to 2015, she served as a Staff Scientist at Eve Biomedical, and from 2011 to 2013, she was a Senior Scientist at Impossible Foods. She conducted her postdoctoral research training at Stanford University. Dr. Vrljic holds a B.S. in Biology from La Roche University and a Ph.D. in Biophysics from Stanford University.
